Rare Disease · In-Market · Updated August 2026
Six prophylaxis agents, five of them clustered near the top of the same efficacy band. Where efficacy converges, positioning has to be argued somewhere else.
Prophylaxis in hereditary angioedema has become a crowded field in which comparative efficacy no longer separates the leading agents. Positioning therefore starts from the contested cohort rather than from a head-to-head claim: which patients are not yet on prophylaxis at all, which are on an agent that does not suit their route or dosing preference, and which are managed on demand.
The unit of value is the avoided attack, and above all the laryngeal attack that drives mortality and emergency cost. Building the case on list price against list price concedes the argument before it starts; converting trial attack-rate reductions into attacks averted, and attacks averted into avoided acute care, is what makes a value story hold with a payer who is already paying for an incumbent.
Two conversions run in parallel and have to be modelled separately. The first moves attack-active patients off on-demand-only management onto any prophylaxis, which is the larger opportunity in markets where on-demand therapy still dominates, including much of the Gulf. The second is the switch onto an oral agent from an injectable, which is a different decision, made by different patients, on different grounds. Treating them as one number produces a forecast that is wrong in both directions.
AXLRx hereditary angioedema reports isolate the never-prophylaxed cohort across the US, UK and Gulf, value agents on attacks averted, and model the two conversions independently. Each report is a sample output of the AXLRx commercial consulting engine, and the same analysis can be commissioned for your asset and market.
For the wider context, see orphan drug approvals in numbers: FDA and EMA orphan approvals counted by year, condition and sponsor.
Hereditary angioedema runs near 1 in 50,000, implying roughly 8,000 to 9,000 US patients, about 85% Type I C1-INH deficiency and 15% Type II. Diagnosed and engaged patients span only 6,000 to 10,000 on HAE Association survey data. The gap widens abroad: a 2023 survey confirms 1,152 UK Type I/II patients across 37 specialist centres against a 5,000 to 6,000 planning estimate, and the GCC confirms fewer than 200 against an implied 1,200 to 1,500. Identification, not prevalence, is the whole commercial story.
Confirmation rests on a low C4 screen, then C1-INH antigenic and functional testing, with SERPING1 sequencing for ambiguous cases. Assay availability is not the obstacle; recognition is. Attacks are misread as ordinary allergic angioedema or abdominal emergencies, producing a mean 8 to 10 year delay that stretches to 12 to 15 years in the GCC. Family cascade screening is the fastest yield, averaging 3.8 relatives per index case in the KFSH&RC registry, yet it stays near-absent where only six to ten specialists cover a region.
Prophylaxis splits by route. Injectable antibodies lead on magnitude: lanadelumab (Takhzyro, Takeda, 2018, HELP ~87%), garadacimab (Andembry, CSL, 2025, VANGUARD ~87%) and donidalorsen (Dawnzera, Ionis, 2025, OASIS-HAE 81%), alongside subcutaneous C1-inhibitor Haegarda (CSL Behring, 2017). Oral berotralstat (Orladeyo, BioCryst, 2020) trades magnitude for convenience at ~44%. On-demand covers oral sebetralstat (Ekterly, KalVista, 2025, 1.6-hour median relief) and the older bradykinin-B2 antagonist icatibant (Firazyr, 2011). Route and dosing, not efficacy ceiling, now separate the field.
Start from diagnosed patients, not epidemiology, then stratify by attack rate. AXLRx builds the funnel from the 6,000 to 10,000 diagnosed US patients down to the 35 to 40% currently prophylaxed, isolating the 2,500 to 4,000 attack-active but never-prophylaxed cohort defined by the three-attacks-per-year or laryngeal-history bar that payers actually apply. A separate 1,000 to 1,500 FXII-HAE and normal-C1-INH subpopulation is carved out because kallikrein-targeted agents serve it less predictably. Each geography inherits its own eligibility gate: the GCC's six-attack NPHC documentation threshold shrinks the pool far below the US line, so the treat-eligible number is a payer construct as much as a clinical one.
Two conversions run in parallel and must be modelled separately. The first moves attack-active patients off on-demand-only management, where C1-inhibitor and icatibant dominate the GCC, onto any prophylaxis; the second moves prophylaxed patients from injectables onto oral agents. AXLRx sizes each with distinct conversion rates, since the never-prophylaxed patient is won on category creation while the injectable-to-oral switch is won on route preference against a stable lanadelumab base holding roughly 45% share. Attacks-averted, acute-therapy offset and administration burden feed the model, and the oral-conversion curve is anchored to berotralstat's observed ~20% uptake rather than a blank-slate assumption.
The unit of value is the avoided attack, above all the laryngeal one that drives mortality and emergency cost. AXLRx converts trial attack-rate reductions, ~87% for lanadelumab and garadacimab, 81% for donidalorsen, ~44% for oral berotralstat, into attacks averted per patient-year, then nets acute-therapy and hospitalisation savings against the $300,000-plus US prophylaxis cost. The result is benchmarked to ICER's ~$95,000 berotralstat fair-value anchor and, in England, to the confidential Patient Access Scheme net prices sitting behind NICE's standard cost-effectiveness bar. The same attacks-averted spine drives the GCC case, where averted laryngeal events justify NPHC individual-case submissions.
Positioning starts from the contested cohort, not head-to-head efficacy, because five of six agents cluster near the top of the efficacy band. AXLRx maps each entrant on the two axes that actually move share: route, injectable magnitude versus oral convenience, and mechanism, plasma-kallikrein, Factor XIIa or antisense. The strategy targets the never-prophylaxed pool, 2,500 to 4,000 in the US and 350 to 500 in the GCC, rather than switching stable patients. Comparator selection then becomes the HTA question: which incumbent a submission must beat, and how to infer a defensible net-price corridor from the few transparent list anchors when every recommended agent's net price stays confidential.
Every answer here is drawn from a connected AXLRx evidence base built for a specific brand decision. A Patient Flow Model isolates the never-prophylaxed cohort across the US, UK and GCC; a Competitive Intelligence read tracks the fracturing prophylaxis and on-demand class; a Disease Landscape sizes biology, attack burden and the diagnostic gap; a Payer and HTA analysis covers specialty-tier prior authorisation, NICE precedent and NPHC individual-case bars; KOL Mapping locates the concentrated specialist centres, five NHS sites and three GCC anchor institutions; and a Pricing Strategy Model reconciles $300,000-plus US costs with confidential UK net prices and GCC tender and VHI channels.